A familial mutation renders atrial natriuretic Peptide resistant to proteolytic degradation
about
Emerging directions in the genetics of atrial fibrillationAtrial natriuretic peptide in cardiovascular biology and disease (NPPA)Innovative Therapeutics: Designer Natriuretic Peptides.In vitro and in vivo pharmacological profile of PL-3994, a novel cyclic peptide (Hept-cyclo(Cys-His-Phe-d-Ala-Gly-Arg-d-Nle-Asp-Arg-Ile-Ser-Cys)-Tyr-[Arg mimetic]-NH(2)) natriuretic peptide receptor-A agonist that is resistant to neutral endopeptidaArg13 of B-type natriuretic Peptide reciprocally modulates binding to guanylyl cyclase but not clearance receptors.Insulin-degrading enzyme modulates the natriuretic peptide-mediated signaling response.A novel atrial natriuretic peptide based therapeutic in experimental angiotensin II mediated acute hypertensionHuman B-type natriuretic peptide is not degraded by meprin A.Natriuretic peptide metabolism, clearance and degradation.Twenty patients including 7 probands with autosomal dominant cutis laxa confirm clinical and molecular homogeneity.Dendroaspis natriuretic peptide and the designer natriuretic peptide, CD-NP, are resistant to proteolytic inactivationRegulation and therapeutic targeting of peptide-activated receptor guanylyl cyclases.M-atrial natriuretic peptide and nitroglycerin in a canine model of experimental acute hypertensive heart failure: differential actions of 2 cGMP activating therapeutics.M-atrial natriuretic peptide: a novel antihypertensive protein therapy.Rationale and therapeutic opportunities for natriuretic peptide system augmentation in heart failure.Antibody tracking demonstrates cell type-specific and ligand-independent internalization of guanylyl cyclase a and natriuretic peptide receptor C.ProBNP(1-108) is resistant to degradation and activates guanylyl cyclase-A with reduced potency.Mass spectrometric identification of phosphorylation sites in guanylyl cyclase A and B.MANP: a novel particulate guanylyl cyclase A receptor/cGMP activator for resistant hypertension: preliminary first in human clinical trial results.
P2860
Q26852051-FD9F7A96-5EF9-44BD-8DFA-F6E5D8DAA668Q28082833-66DC7653-A22B-4CEA-B0ED-7D79CD6EFFBEQ33653332-FA379E0C-EF99-4F8F-A7F9-F954F2EE8696Q33804636-9CA0F1D9-F79B-4B83-B545-0B4C17CA7B61Q34127995-9BCF2E31-CC62-4C9C-BB2E-83F3782A2969Q34575644-29723427-5592-4C6D-9777-E65FF748590BQ35659994-2B6FF41E-261E-4E4F-B44F-A8DDB5BD222BQ35831456-C9F62CC5-4C36-4D5F-8B58-1061C55E3DBEQ35831469-E97A1427-FD32-40FB-B2AE-B6374B21961FQ36688645-0B3D7F19-9AAE-40B0-8FB6-4262BAD45821Q36865781-5F47A832-E546-4FD0-80D6-C7A05EBB0DCAQ36867743-F0A90E4B-64C9-46B9-B210-A77C3D99059CQ37648508-5324527B-3529-46C1-9F57-350D909D2E59Q37963837-E0C230F1-0ED6-4D5C-A81F-0FF906CB0BE7Q38261513-C04C2D47-B929-4524-BE2B-054CA93CEEBFQ39557637-68103D63-EA73-41D1-BDB9-57A55E4D65B4Q40954684-76FE0FE5-0B98-4244-AA52-E76B5EA463D6Q41223771-6D85DACF-6A7C-4429-8897-18879E3C291AQ50353040-6711CAEF-1F4B-48A6-B895-676886063C78
P2860
A familial mutation renders atrial natriuretic Peptide resistant to proteolytic degradation
description
2009 nî lūn-bûn
@nan
2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
A familial mutation renders at ...... ant to proteolytic degradation
@ast
A familial mutation renders at ...... ant to proteolytic degradation
@en
A familial mutation renders at ...... ant to proteolytic degradation
@nl
type
label
A familial mutation renders at ...... ant to proteolytic degradation
@ast
A familial mutation renders at ...... ant to proteolytic degradation
@en
A familial mutation renders at ...... ant to proteolytic degradation
@nl
prefLabel
A familial mutation renders at ...... ant to proteolytic degradation
@ast
A familial mutation renders at ...... ant to proteolytic degradation
@en
A familial mutation renders at ...... ant to proteolytic degradation
@nl
P2093
P2860
P921
P356
P1476
A familial mutation renders at ...... ant to proteolytic degradation
@en
P2093
Andrea R Yoder
Deborah M Dickey
Lincoln R Potter
P2860
P304
P356
10.1074/JBC.M109.010777
P407
P577
2009-07-17T00:00:00Z